Abstract | BACKGROUND: Treatment of Crohn's disease (CD) remains to be a challenge due to limited insights for its pathogenesis. We aimed to determine the role of O-Linked β- N-acetylglucosamine (O-GlcNAc) in the development of CD and evaluate therapeutic effects of O-GlcNAc inhibitors on CD. METHODS: O-GlcNAc in intestinal epithelial tissues of CD, adherent-invasive Escherichia coli (AIEC) LF82-infected cells and mice was determined by immunoblot and immunohistochemistry. AIEC LF82 and dextran sulfate sodium were administrated into C57BL/6 mice for estabolishing inflammatory bowel disease model and for therapeutic study. FINDINGS: O-GlcNAc was increased in intestinal epithelial tissues of CD patients and AIEC LF82-infected mice. Infection of AIEC LF82 up-regulated the level of UDP-GlcNAc and increased O-GlcNAc in human colon epithelial HCT116 and HT-29 cells. We identified that IKKβ and NF-κB were O-Glycosylated in AIEC LF82-treated cells. Mutations of IKKβ (S733A) and p65 (T352A) abrogated the O-GlcNAc in IKKβ and NF-κB and inhibited AIEC LF82-induced activation of NF-κB. Application of 6-diazO-5-oxO-L-norleucine, an agent that blocks the production of UDP-GlcNAc and inhibits O-GlcNAc, inactivated NF-κB in AIEC LF82-infected cells, enhanced the formation of autophagy, promoted the removal of cell-associated AIEC LF82, alleviated intestinal epithelial inflammation, and improved the survival of the colitis mice. INTERPRETATION: Intestinal inflammation in CD is associated with increased O-GlcNAc modification, which is required for NF-κB activation and suppression of autophagy. Targeting O-GlcNAc could be an effective therapy for inflammatory bowel disease. FUNDING: National Natural Science Foundation of China (Nos. 81573087 and 81772924) and International Cooperation Foundation of Jilin Province (20190701006GH).
|
Authors | Qian-Hui Sun, Yi-Shu Wang, Guolong Liu, Hong-Lan Zhou, Yong-Ping Jian, Ming-Di Liu, Dan Zhang, Qiang Ding, Rui-Xun Zhao, Jian-Feng Chen, Yi-Ning Li, Jiyong Liang, Yu-Lin Li, Cheng-Shi Quan, Zhi-Xiang Xu |
Journal | EBioMedicine
(EBioMedicine)
Vol. 53
Pg. 102693
(Mar 2020)
ISSN: 2352-3964 [Electronic] Netherlands |
PMID | 32114385
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- NF-kappa B
- Acetylglucosamine
|
Topics |
- Acetylation
- Acetylglucosamine
(metabolism)
- Animals
- Autophagy
- Crohn Disease
(metabolism)
- Female
- HCT116 Cells
- HT29 Cells
- Humans
- Intestinal Mucosa
(metabolism)
- Male
- Mice
- Mice, Inbred C57BL
- NF-kappa B
(metabolism)
- Protein Processing, Post-Translational
|